Kazia Therapeutics
KZIA
11 hedge funds and large institutions have $1.14M invested in Kazia Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
26% more capital invested
Capital invested by funds: $903K → $1.14M (+$237K)
10% more funds holding
Funds holding: 10 → 11 (+1)
3.55% more ownership
Funds ownership: 10.59% → 14.14% (+3.5%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
+$88.8K |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$19.7K |
| 3 |
Citigroup
New York
|
+$5.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.27K |
| 5 |
Morgan Stanley
New York
|
+$1.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMMA Investing
Foster City,
California
|
-$1.66K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
-$627 |
KZIA Hedge Fund Activity: Q3 2025 in Review
11 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q3 2025, worth a combined $1.14M — up 26% from $903K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KZIA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $88.8K. The largest seller was GAMMA Investing, exiting entirely with an estimated $1.66K sold.
- 11 institutional investors held Kazia Therapeutics (KZIA) as of Q3 2025, up from 10 in Q2 2025.
- Funds reported $1.14M of Kazia Therapeutics stock for Q3 2025, up 26% quarter-over-quarter.
- 3 funds opened new Kazia Therapeutics positions in Q3 2025 and 2 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q3 2025 was Rockefeller Capital Management, an estimated $88.8K added.
- The largest Kazia Therapeutics seller in Q3 2025 was GAMMA Investing, an estimated $1.66K sold.
Based on aggregated 13F filings for Q3 2025.